Literature DB >> 29092058

Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.

Katrin Deumelandt1,2, Michael Platten1,2,3, Katharina Ochs1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29092058      PMCID： PMC5761563          DOI： 10.1093/neuonc/nox169

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.

Authors:  William T Curry; Ramana Gorrepati; Matthias Piesche; Tetsuro Sasada; Pankaj Agarwalla; Pamela S Jones; Elizabeth R Gerstner; Alexandra J Golby; Tracy T Batchelor; Patrick Y Wen; Martin C Mihm; Glenn Dranoff
Journal:  Clin Cancer Res       Date:  2016-02-12       Impact factor: 12.531

4.  A vaccine targeting mutant IDH1 induces antitumour immunity.

Authors:  Theresa Schumacher; Lukas Bunse; Stefan Pusch; Felix Sahm; Benedikt Wiestler; Jasmin Quandt; Oliver Menn; Matthias Osswald; Iris Oezen; Martina Ott; Melanie Keil; Jörg Balß; Katharina Rauschenbach; Agnieszka K Grabowska; Isabel Vogler; Jan Diekmann; Nico Trautwein; Stefan B Eichmüller; Jürgen Okun; Stefan Stevanović; Angelika B Riemer; Ugur Sahin; Manuel A Friese; Philipp Beckhove; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

Review 5.  The Microenvironmental Landscape of Brain Tumors.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

6.  An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.

Authors:  Katherine A Murphy; Melissa G Lechner; Flavia E Popescu; Jessica Bedi; Stacy A Decker; Peisheng Hu; Jami R Erickson; M Gerard O'Sullivan; Lauryn Swier; Andres M Salazar; Michael R Olin; Alan L Epstein; John R Ohlfest
Journal:  Clin Cancer Res       Date:  2012-07-10       Impact factor: 12.531

7.  Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.

Authors:  Nusrat Jahan; Hammad Talat; William T Curry
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

8.  Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.

Authors:  Pankaj Agarwalla; Zachary Barnard; Peter Fecci; Glenn Dranoff; William T Curry
Journal:  J Immunother       Date:  2012-06       Impact factor: 4.456

9.  A therapeutic cancer vaccine against GL261 murine glioma.

Authors:  Mark S Kindy; Jin Yu; Hong Zhu; Michael T Smith; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2016-01-05       Impact factor: 5.531
  9 in total
  3 in total

1.  A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.

Authors:  Jie Xu; Fang Liu; Yuntao Li; Liang Shen
Journal:  Cell Mol Neurobiol       Date:  2020-09-07       Impact factor: 5.046

2.  OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

Authors:  Yayi He; Xiaoshen Zhang; Keyi Jia; Rafal Dziadziuszko; Sha Zhao; Juan Deng; Hao Wang; Fred R Hirsch; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-08

Review 3.  Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.

Authors:  Andy S Ding; Denis Routkevitch; Christina Jackson; Michael Lim
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.